This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk04: Ladies and gentlemen, thank you for standing by. Welcome to the Gameta Cells conference call for second quarter 723 financial results. My name is Michelle and I'll be your operator for today's call. Please be advised that this call is being recorded at Gameta Cells request. And now I would like to introduce your host for today's call, Mike Kuskowski of Gameta Cell Corporate Communications. Mike, please go ahead.
spk09: Thank you, and good morning, everyone.
spk01: Welcome to today's call, during which we will provide an update on the company and review our financial results for the second quarter of 2023. Earlier this morning, we issued a press release summarizing our financial results and providing a business update, which is available on our website at www.gametacell.com. Here with me on our call today are Abby Jenkins, President and Chief Executive Officer, Michelle Corfin, Chief Operating Officer and Chief Commercial Officer, Ronit Simantav, Chief Medical Officer and Chief Scientific Officer, and Terry Coelho, our Chief Financial Officer. Before we begin, I want to remind everyone that during this call, we may make forward-looking statements about our future expectations and plans, including with respect to the product and product candidates, the potentially life-saving or curative therapeutic and commercial potential of GametaCell's product Amasurge, expectations regarding the commercial launch of Amasurge and its potential to capture market share, the company's plans for commercial or strategic partnerships to support the launch of On The Surge, and the company's anticipated financial runway. Our actual results may differ materially from what we project today due to a number of important factors, including those related to clinical, scientific, regulatory, and technical developments, and those inherent in the process of developing and commercializing products and product candidates that are safe and effective for human use as human therapeutics, and in the endeavor of building a business around our product and product candidates as well as those considerations described in the risk factors section of our most recent quarterly report on Form 10-Q and other filings that we may make with the SEC from time to time. These forward-looking statements represent our views only as of today, and we caution you that we may not update them in the future, whether as a result of new information or future events, except as required by applicable law. Now, I will turn the call over to our President and CEO, Abby Jenkins. Abby?
spk08: Thank you, Mike, and everyone joining us today. I'll begin by providing a brief corporate update. I know many of you are wondering how our launch is progressing. Well, we've made remarkable progress since the FDA approval of OmniSurge in April. We are seeing a very high level of interest and engagement from transplant centers and are exceeding expectations with transplant center onboarding, as Michelle will discuss in more detail shortly. As of this morning, we have onboarded 12 transplant centers and have eight additional transplant centers currently in the onboarding process against a goal of 10 to 15 for the year. That is tremendous progress for our first four months of launch. We've confirmed coverage with US payers that cover more than 85% of commercial lives. This includes confirmed national coverage with nine out of the top 10 payers. In June, we confirmed coverage and reimbursement for AmiSurg with Medicare. This means the vast majority of patients now have coverage in place for OmniSurg. We are thrilled with the progress we are making on the launch of OmniSurg. This demonstrates that there is significant interest from transplanters to have OmniSurg available as a donor source option for patients. And it signals that the real world potential of OmniSurg is consistent with the market research we conducted prior to and just after approval. In fact, Based on this progress, we plan to hire four account managers and two additional medical science liaisons, or MSLs, to join the existing team of four account directors and four medical science liaisons to further support the demand for OmniSurge. As many of you know, we hosted an Investor Day on June 29th to discuss the unmet need in stem cell transplantation and the role OmniSurge may play in addressing those needs. We were joined by two thought leaders in stem cell transplantation, Dr. Steven Devine, Chief Medical Officer at the National Marrow Donor Program, Be The Match, and Senior Scientific Director at the CIBMTR, the Center for International Blood and Marrow Transplant Research, and Dr. Usama Girgis, Professor of Oncology and Director of Transplant and Cellular Therapy at the Sidney Kimmel Cancer Center at Thomas Jefferson University in Philadelphia. Dr. Devine addressed the unmet need regarding access to stem cell transplant. He explained that while approximately 20,000 people are eligible each year for transplant, only about half of these patients actually receive one. He outlined a variety of barriers, including highlighting the inequities in access for patients who are racially or ethnically diverse, and OmniSurg's potential to help expand access and address those health disparities. Our phase three study had over 40% of patients who were racially and ethnically diverse, which demonstrates both the unmet need and also AmiSurge's ability to be a viable donor source for these patients. Dr. Devine concluded that today, no patient should go without a potentially curative transplant because they can't find a match. Dr. Griggs's presentation was especially poignant. He shared the story of his patient who was eligible for a stem cell transplant a year and a half ago, but struggled to find a donor, illustrating the need for AmiSurg as a new donor source. This person was a young black patient who could not find a match from a family member. Unfortunately, the only options available to this patient were mismatched unrelated donors. Throughout this talk, Dr. Gergis explained that timing is key with transplants. as the patient could potentially relapse and become ineligible for transplant or become too weak to withstand the transplantation process. He said that if he was treating this patient today, he likely would have chosen AmiSurge as the donor source and highlighted the 30-day turnaround for AmiSurge as a positive benefit. Dr. Gervais also discussed a decision tree research model developed in partnership with GametaCell, evaluating outcomes in patients undergoing transplants. The research showed that availability of Omnisurg at a 20% peak market share may increase transplant access, particularly for patients who are racially and ethnically diverse, demonstrating a 25% overall increase in allogeneic stem cell transplant rates with the degree of benefit largest for Black patients and those of Asian, Hispanic, and multiracial backgrounds. This makes us very optimistic about the potential role AmiSurg may have in addressing what we estimate to be about 1,700 patients who are eligible for stem cell transplant annually, but for whom, but for who are unable to find a donor. That's in addition to the transplanters potentially choosing AmiSurg instead of other donor sources. As we heard from both Dr. Gerges and Dr. Devine, there is a clear need for AmiSurg. which we believe is reflected in the launch progress we're seeing. We remain committed to our two-pronged corporate strategy announced at the end of March, which involves, first, launching OmniSurge in the U.S. with the goal of onboarding 10 to 15 transplant centers by the end of 2023, a goal we now expect to meet at RICSEED, and secondly, pursuing a strategic partnership or transaction with a biopharmaceutical company to expand transplant center onboarding and accelerate patient access to AmiSurg. On the second part of that strategy, we are continuing conversations with potential strategic partners. We believe our early launch success is a promising sign of AmiSurg's long-term potential. On board to help with these efforts is our recently appointed Chief Financial Officer, Terry Coelho, who joined the team in May. Terry is a seasoned finance executive with over 35 years of experience across all areas of finance and business development at both emerging growth and established global companies. She was most recently Executive Vice President, CFO, and Chief Business Development Officer at Syncor Pharma Inc., where she led the company's successful initial public offering and follow-on financing in 2022. She's also held senior financial and executive roles at several other companies, including Novartis Pharmaceuticals, where for close to eight years, she held roles of increasing responsibility, including as finance lead for the oncology hematology franchise, and later led the global oncology development finance function. We are thrilled to have Terri on board to support GametaCell's ongoing transition into a commercial stage company and help drive our strategic partnership efforts. In addition, the GamitaCell Board of Directors appointed Jeremy Blank, Founding Partner and Chief Investment Officer of Community Fund, to the board. Community Fund is a significant shareholder in GamitaCell. Jeremy has deep experience as an investment advisor for both companies and investors, and we believe he is well-positioned to help the board support our execution of GamitaCell's corporate strategy to identify the right partner to fully resource the launch of OmniSurge. Jeremy believes strongly in our two-pronged corporate strategy. In terms of our current financial position, we are pleased to share that we have strengthened our balance sheet significantly in the past quarter, enabling us to effectively drive our launch efforts while also extending our cash runway into Q2 of 2024. You'll hear more details on our financials from Terry in just a moment. So to summarize, we have made significant progress on the commercial launch of Army Surge exceeding expectations in terms of both securing payer coverage and onboarding transplant centers. We heard inspiring testimony from external thought leaders about AmiSurg's potential to increase access and address barriers to care for patients in need of a stem cell transplant at our recent investor day. And it's delightful to say that we have heard similarly positive feedback from transplant centers during our onboarding process. We continue to progress our discussions to secure a business development transaction, and we are thrilled to have Terry on board as our new CFO. We are confident in our team's ability to deliver OmniSearch to patients and its potential to save lives. I'll now turn the call over to Michelle for a more in-depth update on our commercial launch. Michelle, over to you.
spk07: Thank you, Abby, and good morning, everyone. Ganita Cell continues to advance efforts and prioritize resources across the organization to execute AlmaSurge's launch and ensure patients in need could have access to AlmaSurge. We are pleased to share that the launch is off to a great start. Our real-world launch experience is consistent with both our pre and post-approval market insights, both in terms of unmet needs with existing donor sources and interest in Omasurge from transplanters and the multidisciplinary teams at their centers. As you may recall, Gameta Cell conducted a total of five independent blinded market insight studies with healthcare providers and payers, both pre- and post-approval. That showed Omasurge has the potential to capture approximately 20% market share at peak, which we estimate could occur by 2028. The insights were consistent that the market share capture for Omasurge could come from transplanters using Omasurge instead of other donor sources, as well as transplanters using Omasurge for those approximately 1,700 patients who are eligible for transplant each year and could not find an appropriate donor. Although we previously estimated this number to be about 1,200, we now have independent data that show it is more likely about 1,700 patients each year who cannot find an appropriate donor. As a reminder, a patient with a hematologic malignancy goes to transplant since that may be their only potential remaining treatment option. For those approximately 1,700 patients who could not find a donor, they will most likely succumb to their disease. We are passionate at Gameta about making sure transplant centers have access to Omasurge as a potential option for their patients. Today, and in the past few months since approval, we have seen very strong interest in Omasurge from transplant centers, including centers that were not part of the phase three trial. As of this morning, 12 transplant centers have been onboarded, including centers such as Duke University Medical Center, Jefferson Health in Philadelphia, The Ohio State, and UCLA Health. And eight additional transplant centers are actively in the onboarding process. We are engaged with virtually all of the top 70 centers, which conduct about 80% of the transplants in the US. I am very excited to say that GametaCell remains on track to possibly exceed our goal of onboarding 10 to 15 transplant centers by the end of 2023, and that we have exceeded our expectations with regard to the number of centers onboarded to date. Our transplant center onboarding team works closely with transplant center personnel on the clinical training and administrative policies and procedures required to begin using Omasurge as a donor source. How quickly a transplant center is onboarded is determined by the needs of each individual transplant center. This can include factors like staff availability to participate in the onboarding and the status of patients currently under evaluation who may be good candidates for Omasurge. Our team is nimble and customizes onboarding timelines to meet individual transplant center and patient needs. The clinical approach and policies and procedures needed for Omasurge are consistent with other donor sources and are therefore very familiar to transplant center personnel. So ultimately the onboarding process can be completed very quickly, typically more quickly than for other cell therapies. We have also been focused on ensuring payer coverage for almost search. We have confirmed coverage for the vast majority of patients in the US. In fact, more than 85% of commercial lives have confirmed coverage. This includes national coverage with nine out of the top 10 payers. And we are in ongoing discussions with additional commercial payers to further expand coverage. Last year, we secured our OMA search-specific ICD-10 codes, and in June, we announced that we now also have confirmed CMS coverage and reimbursement for patients covered by Medicare. We also have all the required documentation in place for patients who are covered under Medicaid, the Department of Defense, and the Department of Veteran Affairs. We know from our clinical trials and working in transplant that it takes time to evaluate patients and get them ready for transplant. This is true for all donor sources, and the specific timeline and approach for preparing a patient for transplant can vary by transplant center based on each center's policies and procedures. I am excited to share that patients are enrolled in the Gameta Cell Assist Program. which was created to ensure healthcare providers and patients could access therapy and have a personalized positive experience. When a transplant physician enrolls a patient in gametophilicis, it signals that they intend to use Omasurge as the patient's donor source. The transplant centers enroll patients in gametophilicis, select Omasurge, and schedule their manufacturing dates. and can also work with GametaCell Assist for patient assistance, including benefit verification, patient support programs, and copay or coinsurance assistance. This is a significant step for the patient in terms of their journey to transplantation. Once the Omasurge donor source is selected by the patient's transplanter and the cord blood unit is received by GametaCell, we are ready to begin manufacturing. As a reminder, we have been successfully manufacturing clinical batches in our facilities for over a year. We have an experienced team in place, and we are ready to reliably deliver Omasurge within 30 days from the start of manufacturing. To continue the rapid expansion of our commercial launch and support the demand for Omasurge, we have plans to hire four account managers and two additional medical science liaisons to support the current team of four regional account directors and four MSLs. We feel this is an appropriate investment to capitalize on the momentum and interest we are seeing from transplant centers. Going back to our mission, GametaCell was built to deliver potentially curative therapies for patients with blood cancers. Omasurge is a core element in delivering on that mission based on its potential to increase access and address critical unmet needs in stem cell transplantation. We are prioritizing every resource possible to support this launch, knowing the meaningful impact Omasurge can potentially have on patients' lives. The interest and enthusiasm from transplant centers are both gratifying and supportive of the pre-launch market insights Our team at GametaCell has been working hard to meet transplant center demand and ensure that every patient in need of a stem cell transplant has access to AlmaSearch. With that, I'd like to turn the call over to Ronit Simontov, our Chief Medical and Chief Scientific Officer. Ronit.
spk06: Thank you, Michelle, and good morning, everyone. Thank you for joining us today. My team and I have been speaking with physicians across the country. And the feedback we hear on Omisurge echoes what Michelle has shared. We see a clear need for transplant options for their patients and are eager to make Omisurge available at their institutions. Today, I will provide a few updates on recent data for Omisurge and for our NK Cell Therapy candidate, GDA201. First, results of a prospective sub-study of the Phase III Omisurge trials were recently published in the journal Transplantation and Cellular Therapy. Our phase three study, which over 40% of patients were members of ethnic and racial minority groups, demonstrated rapid neutrophil engrossment, a key early marker of transplant success, and lower rates of serious infection in patients transplanted with Omisurge compared to cord blood. Using real-world data from CIBMTR, we also showed that transplantation with Omisurge led to faster hematopoietic recovery than other donor sources. A potential mechanism for these observations was elucidated in a sub-study of 37 patients from the Phase III trial, which showed prompt and robust recovery of immune cells after transplant with Omisurge, with up to a 70-fold advantage in median cell counts across most cell populations, including NK, T, and B cells. The authors concluded that the faster recruitment and development of immune cells may account for the reduced rate of bacterial, fungal, and viral infections observed after transplantation with Omasurge versus cord blood. We continue to present and publish data that add to the scientific and clinical understanding of Omasurge and provide insights to the transplant community. I'll now turn to GDA201, our allogeneic NK cell therapy candidate, derived from adult donors and manufactured using our proprietary nicotinamide or NAMM technology. We presented data at the International Society for Cell and Gene Therapy, or ISCT, 2023 annual meeting in June, demonstrating the robustness of cryopreserved GDA201. We showed that NAMM expansion of NK cells led to the expression of lymphoid homing marker CD62 ligand and decreased levels of lineage exhaustion markers CD57 and CD161, providing further phenotypic characterization of GDA201. In addition, data from the investigator-led study at the University of Minnesota using the fresh formulation of GDA201 were published in the July 19th edition of Science Translational Medicine. The publication included preclinical, clinical, and translational data. The preclinical data demonstrated that our NAMM technology increased metabolic fitness, energy charge, and glucose flux in NK cells. The implications of these findings are significant, given recent research showing the importance of metabolic fitness in cellular therapy. The clinical data shows 74% overall response rate and 57% complete response rate in heavily pretreated patients with non-Hodgkin lymphoma treated with GDA201. And translational data in biopsy specimens showed that tumor regression was associated with dense host T cell infiltration into lymph node tissue after GDA201 treatment, suggesting that GDA201 generated an adaptive immune response in patients. These data provide further evidence that GDA201 NK cells, which originate from human donors and are expanded using our NAM technology, can overcome the historic limitations of NK cells as a viable therapeutic. We're excited about these new insights on metabolic fitness, cytotoxicity, and engagement of the adaptive immune system as we proceed with our phase one dose escalation study of GDA201. We are enrolling patients with non-Hodgkin lymphoma at six U.S. sites and expect to report data in the first quarter of 2024. I will now turn the call over to Terry Coelho, our Chief Financial Officer. Terry?
spk03: Thank you, Renit, and good morning, everyone. As Abby mentioned earlier, I'm pleased to share that the company has strengthened its balance sheet in the second quarter. We ended the second quarter with $54.1 million in cash as a result of combined net proceeds of $34.7 million from both the April equity offering and funds raised using the at-the-market or ATM facility in the quarter. In addition, the outstanding principal balance of our 2022 $25 million convertible term loan was $10 million as of June 30, 2023, a reduction of $9 million as compared to the balance of $19 million at the end of the first quarter. The $9 million reduction reflects primarily voluntary share exchanges by the lender in addition to the payment of a monthly installment in shares. The combined principal balance of the 2022 note and the $75 million senior convertible note is $85 million as of June 30th, down from $94 million at the end of the first quarter. Research and development expenses were $8.7 million in the second quarter of 2023 compared to $10.6 million in the same quarter in 2022. The decrease of $1.9 million was primarily due to a $1.6 million reduction associated with the discontinuation of development of our engineered NK cell therapy pipeline, and $700,000 in lower AMA surge phase three spend, including a decrease in payments for manufacturing services, partially offset by a decrease of $400,000 in Israeli Innovation Authority income. Commercial expenses were $3.9 million in the second quarter of 2023 compared to $3.2 million in the second quarter of 2022. The increase of $700,000 was attributable to an increase in launch readiness activities. General and administrative expenses were $6.3 million in the second quarter of 2023 compared to $4.3 million in the same period in 2022. The increase of $2 million was associated with higher professional services expenses of $1 million, in part due to the April follow-on offering and business development activities. Financial expenses were $12.9 million net in the second quarter of 2023, compared to $500,000 in the same period of 2022. The increase of $12.4 million was primarily due to non-cash expenses totaling approximately $10.4 million, including the fair value impact on our warrants liability of $4.9 million, the fair value impact on the 2022 convertible note of $4.3 million, and a decrease in capitalization of finance costs to fixed assets of $600,000. In addition, the increase was due to higher cash expenses of $2 million, including $1.7 million in issuance costs from our April 2023 underwritten public offering and an increase of $1 million in interest expenses associated with the 2022 convertible note. partially offset by increased interest income of $500,000. Our net loss was $31.7 million in the second quarter of 2023, compared to a net loss of $18.6 million in the second quarter of 2022, driven primarily by the increase in financial expenses of $12.4 million. As I mentioned before, as of June 30th, 2023, Gameta Cell had total cash and cash equivalents of $54.1 million compared to $64.7 million as of December 31st, 2022. The decrease of $10.4 million is due primarily to net cash used in operating activities of $44.3 million, partially offset by $34.7 million in net cash proceeds from the issuance of shares and warrants in our underwritten public offering along with the issuance of shares via the ATM facility. Subsequent to the quarter close and through August 9th, the company raised an additional $14 million in net proceeds via the ATM facility. The company expects its current cash and cash equivalents, including the funds raised via the ATM subsequent to the close of the second quarter, to support its ongoing operating activities into the second quarter of 2024. Based on Comita Sales' current operational plans, and excluding commercialization activities beyond the initial launch of AmaSurge, as well as any additional financing activities that may be undertaken. We believe that this cash runway will enable us to effectively support the launch of AmaSurge while pursuing strategic alternatives. With that, I'll turn the call back over to Abby for some concluding remarks. Abby?
spk08: Thank you, Terry. Before I turn the call over to the operator for questions, I want to bring us back around to the beginning of the call and summarize the key points from our discussion today. We've made great progress on the commercial launch of OmniSurg. We are on track to possibly exceed our goal of onboarding 10 to 15 transplant centers this year, which is the first prong of our two-pronged strategy. And we have confirmed coverage from payers that cover more than 85% of commercial lives. along with securing Medicare coverage and reimbursement. We are also continuing to execute on the second prong of our strategy to pursue a strategic partnership or transaction in order to expand transplant center onboarding and accelerate patient access to OmniSurg. Conversations with potential strategic partners are ongoing. The phase one clinical trial for GDA201 is proceeding as expected, and we look forward to the data readout in early 2024. We have strengthened our balance sheet significantly, enabling us to effectively drive these efforts and extending our cash runway into Q2 of 2024. Most importantly, we are thrilled that patients now have access to a new stem cell donor source. We believe our early launch success is a promising sign of Omnisurg's long-term potential to increase access and address critical unmet needs in stem cell transplantation. Now, let's open the call for questions. Operator?
spk04: Thank you. If you would like to ask a question, please press star 1-1. If your question has been answered and you'd like to remove yourself from the queue, please press star 1-1 again. Our first question comes from Jason Butler with JMP Securities. Your line is open.
spk02: Hi. Thanks for taking the questions and congrats on all the progress. I'm just wondering if you have more color on the patients that are already in the Gametacel Assist program. Where along the process towards treatment are there, and what would need to happen between now and them actually getting treated, or between now and you actually starting the manufacturing process for these patients?
spk00: Thanks.
spk07: Hi, good morning, Jason. It's Michelle, and thank you for the question. So, we do have patients enrolled in comedicillis cysts, so hence the commercial manufacturing process is now underway. From the standpoint of just a reminder, we have successfully manufactured Omasurge for about a year at this facility for both our EAP and clinical trials. So, the team is excited to now have the commercial manufacturing process started too. So, Jason, let me pause there and see if I fully addressed your question.
spk02: Yeah, I guess just to clarify, does that mean that you already have reimbursement approval for these patients? And then can you, if you can, can you give us a sense of the patients in you meet or assist now? Are they more heavily weighted towards commercial plans or Medicare? Thanks.
spk05: Yeah, excellent questions. So, let's start with both coverage and. Could you, okay, Jason, could you hear me okay?
spk02: Yeah.
spk07: Okay, perfect. Great. So, let's start with coverage and reimbursement, and then we'll talk about the patient mix. So, from the standpoint of coverage and reimbursement, we're very encouraged with where we stand on both the commercial side and the CMF side. So, let me start with commercial. So, coverage, we have... We have confirmed coverage for commercial payers who cover over 85% of the commercial lives. So that's the coverage.
spk05: From a reimbursement standpoint, what we're hearing so far from the centers is they're generally working with their respective payers, utilizing single case agreements.
spk07: Those that have gone through already have gone through very smoothly and consistent with expectations from both the payer side and the center side. So that's the reimbursement side on the commercial side. Coverage and reimbursement for CMS or Medicare specifically, we did receive our ICD-10 codes last year, and coverage was mapped to DRG-14, which is where we would expect it to be for an allogeneic stem cell transplant. And in June, we received confirmation from CMS that reimbursement will be covered under the legislation that led to Section 108, and that covers donor sources as a pass-through. So from the standpoint of Medicare, we have both the confirmed coverage and reimbursement. You know, you ask about the patients that are in gamete cell assist. We've seen a mixture of commercial and CMS patients. And, yeah, as I mentioned, we're very encouraged by both the confirmed coverage and also the reimbursement process to date on both the commercial and the Medicare side.
spk02: Great. And then just last one from me. If you hit the target of onboarding centers this year, do you have the resources to continue to on board centers above that initial target? Thanks.
spk07: Yeah, so as we mentioned in our prepared remarks, we are adding additional account managers. So four commercial account managers, and Roni and her team are adding additional MSLs. And your question is very astute. We do need to make sure that as that level of interest from centers continues to grow, which we're very encouraged by, that we have the appropriate resources So hence the additional resources that we'll be adding on both the account manager and MSL side.
spk02: Okay, great. Thanks for taking the questions.
spk09: Thank you.
spk07: Gil was next in the queue.
spk10: Hi, this is Ethan on for Gil. Thank you for taking our question. I was just wondering, If you could tell us, based on the 12 centers onboarded so far, how many of those are previously involved in clinical studies versus those not? Because I know that was a previous point at the analyst day. And then the second question is, during the analyst event, I believe you guided that first commercial manufacturing might initiate in the third quarter. I was wondering if you were still on track for that or if that's changed. Thank you.
spk07: This is Michelle, and thank you for the question. I'll take the first one in regards to the 12 centers onboarded and clinical study participation. The vast majority of the centers onboarded were not in the clinical study. So, yeah, we're very encouraged by the fact that we have the strong level of interest from centers who are not part of the clinical studies. And, you know, our medical team has worked very closely with them, as have our commercial team for onboarding. So that's the first question. You know, the second question, you know, we do have patients enrolled in Gameta Cell Assist. So, hence, once they are enrolled in Gameta Cell Assist, the commercial manufacturing process does initiate. Let me stop there. Excellent. Thank you.
spk09: As a reminder, if you'd like to ask a question, please press star 1-1. Okay, I think, well, that concludes our Q&A.
spk04: If there are no further questions, I'd like to turn the call back over to Abby Jenkins, President, CEO, for closing remarks.
spk08: Thank you all again for joining us. To recap, just a few months after FDA approval of Omisurge, Gametacel is well positioned to bring Omisurge to patients with hematologic malignancies in need of a stem cell transplant in transplant centers across the country. Our team at GametaCell is working hard to meet the significant interest we are seeing from transplant centers, and we are so excited at the prospect of bringing OmniSearch to patients. Thank you, everyone, for joining us on today's call, and we look forward to providing further updates on future calls. Thank you.
Disclaimer